JP2015521592A - 安定化されたｇｐ１２０ - Google Patents

安定化されたｇｐ１２０ Download PDF

Info

Publication number
JP2015521592A
JP2015521592A JP2015516648A JP2015516648A JP2015521592A JP 2015521592 A JP2015521592 A JP 2015521592A JP 2015516648 A JP2015516648 A JP 2015516648A JP 2015516648 A JP2015516648 A JP 2015516648A JP 2015521592 A JP2015521592 A JP 2015521592A
Authority
JP
Japan
Prior art keywords
polypeptide
hiv
stabilized
isolated polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015516648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521592A5 (enExample
Inventor
アンドレア カルフィ，
アンドレア カルフィ，
アンツ デイ，
アンツ デイ，
アエムロ カッサ，
アエムロ カッサ，
インドレッシュ スリバスタバ，
インドレッシュ スリバスタバ，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015521592A publication Critical patent/JP2015521592A/ja
Publication of JP2015521592A5 publication Critical patent/JP2015521592A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015516648A 2012-06-18 2013-06-17 安定化されたｇｐ１２０ Pending JP2015521592A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
US61/661,050 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (2)

Publication Number Publication Date
JP2015521592A true JP2015521592A (ja) 2015-07-30
JP2015521592A5 JP2015521592A5 (enExample) 2016-08-04

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516648A Pending JP2015521592A (ja) 2012-06-18 2013-06-17 安定化されたｇｐ１２０

Country Status (14)

Country Link
US (1) US20150183835A1 (enExample)
EP (1) EP2861249A1 (enExample)
JP (1) JP2015521592A (enExample)
KR (1) KR20150023735A (enExample)
CN (1) CN104619338A (enExample)
AU (1) AU2013279456A1 (enExample)
CA (1) CA2876762A1 (enExample)
IL (1) IL235898A0 (enExample)
IN (1) IN2014KN02740A (enExample)
MX (1) MX2014014682A (enExample)
RU (1) RU2015101081A (enExample)
SG (1) SG11201407995RA (enExample)
WO (1) WO2013189901A1 (enExample)
ZA (1) ZA201408840B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533449A (ja) * 2016-10-21 2019-11-21 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５に基づく分子

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
US10010605B2 (en) * 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3426291A1 (en) 2016-03-09 2019-01-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
EP3697440A1 (en) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542146A (ja) * 1998-11-27 2002-12-10 アンスティテュ ド ルシェルシュ プール ル デヴロプマン （イ．アール．デ） ｇｐ１２０の変異体とそれらの生物学的応用
JP2003509013A (ja) * 1999-06-25 2003-03-11 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド 安定化されたウィルスエンベロープタンパク質とその使用
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175070B2 (en) * 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542146A (ja) * 1998-11-27 2002-12-10 アンスティテュ ド ルシェルシュ プール ル デヴロプマン （イ．アール．デ） ｇｐ１２０の変異体とそれらの生物学的応用
JP2003509013A (ja) * 1999-06-25 2003-03-11 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド 安定化されたウィルスエンベロープタンパク質とその使用
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FINZI A ET AL: "Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered confo", MOLECULAR CELL, vol. 37, no. 5, JPN6017015256, 2010, pages 656 - 667, XP055084948, ISSN: 0003547740, DOI: 10.1016/j.molcel.2010.02.012 *
KASSA A ET AL: "Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the H", J VIROLOGY, vol. 83, no. 17, JPN6017015257, 2009, pages 8364 - 8378, XP055007117, ISSN: 0003547741, DOI: 10.1128/JVI.00594-09 *
KWON YD ET AL: "Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaterna", PROC NATL ACAD SCI USA, vol. 109, no. 15, JPN6017015262, April 2012 (2012-04-01), pages 5663 - 5668, XP055084808, ISSN: 0003547743, DOI: 10.1073/pnas.1112391109 *
PANCERA M ET AL: "Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basi", PROC NATL ACAD SCI USA, vol. 107, no. 3, JPN6017015254, 2010, pages 1166 - 1171, XP055084839, ISSN: 0003547739, DOI: 10.1073/pnas.0911004107 *
XIANG SH ET AL: "Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the", J VIROLOGY, vol. 76, no. 19, JPN6017015260, 2002, pages 9888 - 9899, XP055085243, ISSN: 0003547742, DOI: 10.1128/JVI.76.19.9888-9899.2002 *
ZHOU T ET AL: "Structural definition of a conserved neutralization epitope on HIV-1 gp120", NATURE, vol. 445, no. 7129, JPN6017015252, 2007, pages 732 - 737, ISSN: 0003547738 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533449A (ja) * 2016-10-21 2019-11-21 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５に基づく分子
JP7492336B2 (ja) 2016-10-21 2024-05-29 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ－１５に基づく分子

Also Published As

Publication number Publication date
KR20150023735A (ko) 2015-03-05
AU2013279456A1 (en) 2014-12-18
SG11201407995RA (en) 2015-01-29
WO2013189901A1 (en) 2013-12-27
IL235898A0 (en) 2015-01-29
ZA201408840B (en) 2016-08-31
IN2014KN02740A (enExample) 2015-05-08
CA2876762A1 (en) 2013-12-27
MX2014014682A (es) 2015-03-04
US20150183835A1 (en) 2015-07-02
CN104619338A (zh) 2015-05-13
RU2015101081A (ru) 2016-08-10
EP2861249A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
US12606596B2 (en) Self-assembling insect ferritin nanoparticles
US11786591B2 (en) Recombinant metapneumovirus F proteins and their use
AU2017225144B2 (en) N-Terminal Deleted GP120 Immunogens
US20150183835A1 (en) Stabilized gp120
KR102713707B1 (ko) 신규 다가 나노입자 기반 백신
AU2014259474B2 (en) Stabilized soluble prefusion RSV F polypeptides
JP2023515800A (ja) コロナウイルス感染症２０１９（ｃｏｖｉｄ－１９）の検出、予防及び治療のためのデザイナーペプチド及びタンパク質
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
AU2020367242B2 (en) Influenza virus vaccines and uses thereof
US11872277B2 (en) Compositions and methods related to ebolavirus vaccines
US9707290B2 (en) Immunogens of HIV-1 broadly neutralizing antibodies, methods of generation and uses thereof
Gao et al. Centralized HIV-1 envelope immunogens and neutralizing antibodies
JP2008511331A (ja) 修飾されたｈｉｖ−１エンベロープタンパク質
JP7167088B2 (ja) インフルエンザウイルスワクチンおよびその使用
WO2024061188A1 (zh) 一种冠状病毒多价疫苗及其应用
WO2024036217A2 (en) Immunization strategies to more naturally guide the maturation of antibodies against human immunodeficiency virus (hiv) in hiv-infected subjects
EA046906B1 (ru) Вакцины против вируса гриппа и пути их применения
WO2025144636A1 (en) ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2017007646A1 (en) Hiv-1 clade c envelope glycoproteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180131